dave297
03 Feb 2016
GSK Good to see the Ellipta range of products get a mention as performing strongly in the headline summary of GSK s Finals ,out today
dave297
28 Jan 2016
Re: Mundipharm I suppose if they thought there was any prospect of Fluti making it in the US Mundi ( & associated companies) would again be the perfect partner but they clearly do not consider,currently, that we can progress there.
dave297
28 Jan 2016
Re: Mundipharm Had not previously heard of The Sacklers but brief research tells me they are one of the wealthiest dynasties in the world !I have no objection to a reverse takeover but preferably following our SP increasing to a substantially higher level over the next year or two !
oldjoe1
28 Jan 2016
Re: SKP, Broker Update. N+1 Singer Reiterates “Corporate” Rating for SkyePharma PLC (SKP)January 28th, 2016 • 0 comments • Filed Under • by ABMN StaffSkyePharma PLC logoSkyePharma PLC (LON:SKP)‘s stock had its “corporate” rating reiterated by N+1 Singer in a research report issued to clients and investors on Thursday, Market Beat Ratings reports.Shares of SkyePharma PLC (LON:SKP) opened at 393.2500 on Thursday. The firm’s market cap is GBX 412.13 million. SkyePharma PLC has a 52 week low of GBX 247.00 and a 52 week high of GBX 414.45. The firm’s 50-day moving average price is GBX 373.99 and its 200-day moving average price is GBX 328.49. Other research analysts also recently issued research reports about the company. Stifel Nicolaus reiterated a “buy” rating and set a GBX 460 ($6.55) price target on shares of SkyePharma PLC in a report on Thursday. FinnCap reiterated a “buy” rating on shares of SkyePharma PLC in a report on Friday, January 22nd. Finally, RX Securities reiterated a “buy” rating on shares of SkyePharma PLC in a report on Wednesday, December 23rd.Skyepharma PLC (LON:SKP) is a specialty pharmaceutical company. The Company is engaged in the development and delivery of oral and inhalation pharmaceutical products. The Company’s products pipeline includes four inhalation products, 10 oral products, one topical product and one injectable product. The Company’s products include flutiform, Exparel, Paxil CR, Sular, Diclofenacratiopharm, Madopar DR and Coruno, among others. The Company’s product flutiform is a multi-dose pressurized metered dose inhaler, utilizing SkyeDry technology, containing steroid (fluticasone) and a beta agonist (formoterol). flutiform is indicated for the treatment of asthma. Exparel is a bupivacaine injectable product indicated for post-surgical pain management. The Product utilizes Pacira Pharmaceuticals’ DepoFoam technology. The Company has approximately 10 approved oral products that are sold in over 80 countries.
oldjoe1
28 Jan 2016
SKP, Broker Update. <b>SkyePharma PLC’s (SKP) “Buy” Rating Reiterated at Stifel NicolausJanuary 28th, 2016 • 0 comments • Filed Under • by ABMN Staff</b>SkyePharma PLC logoSkyePharma PLC (LON:SKP)‘s stock had its “buy” rating reaffirmed by investment analysts at Stifel Nicolaus in a note issued to investors on Thursday, MarketBeat reports. They presently have a GBX 460 ($6.55) price objective on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 17.50% from the stock’s current price.A number of other research firms have also recently commented on SKP. N+1 Singer restated a “corporate” rating on shares of SkyePharma PLC in a report on Wednesday, December 16th. RX Securities restated a “buy” rating on shares of SkyePharma PLC in a report on Wednesday, December 23rd. Finally, FinnCap restated a “buy” rating on shares of SkyePharma PLC in a report on Friday, January 22nd. Shares of SkyePharma PLC (LON:SKP) opened at 393.2500 on Thursday. The stock has a 50 day moving average of GBX 373.99 and a 200-day moving average of GBX 328.49. SkyePharma PLC has a 52 week low of GBX 247.00 and a 52 week high of GBX 414.45. The company’s market capitalization is GBX 412.13 million.Skyepharma PLC (LON:SKP) is a specialty pharmaceutical company. The Company is engaged in the development and delivery of oral and inhalation pharmaceutical products. The Company’s products pipeline includes four inhalation products, 10 oral products, one topical product and one injectable product. The Company’s products include flutiform, Exparel, Paxil CR, Sular, Diclofenacratiopharm, Madopar DR and Coruno, among others. The Company’s product flutiform is a multi-dose pressurized metered dose inhaler, utilizing SkyeDry technology, containing steroid (fluticasone) and a beta agonist (formoterol). flutiform is indicated for the treatment of asthma. Exparel is a bupivacaine injectable product indicated for post-surgical pain management. The Product utilizes Pacira Pharmaceuticals’ DepoFoam technology. The Company has approximately 10 approved oral products that are sold in over 80 countries.
bamboozled
28 Jan 2016
Re: Mundipharm Yes.d297. Part of the Sackler dynasty. They own Napp Pharma in the UK and traditionally are pain specialists (oxycontin etc) and only recently entered the asthma business when fluti was launched.I worked for them for a couple of years.
dave297
28 Jan 2016
Mundipharm Interesting company & seemingly controlled by a couple of "old boys" of about 80.Substantial private company with substantial turnover,assets,cash in bank & profits.Wonder what their succession plans may be & whether or not they would have any interest in SKP paper, 1 day ?
oldjoe1
28 Jan 2016
Re: SKP, GOOD DEAL........... SkyePharma PLC SKP Stifel Buy 395.13 392.25 460.00 460.00 ReiteratesSkyePharma PLC SKP N+1 Singer Corporate 395.13 392.25
Ambiorix1
28 Jan 2016
Re: Good News ? Good news indeed Dave,Taking care of Asthma sufferers is one of the specialities of Mundipharma. Since they are already selling Flutiform in almost the rest of the world, they know the potential far better than anyone else. For Sanofi, selling Flutiform was probably just some peanuts with little room for global expansion unless they intend to take over Mundipharma.I see it as a positive move.Ambiorix
oldjoe1
28 Jan 2016
SKP, GOOD DEAL........... BRIEF – Skyepharma ties with Mundipharma for Flutiform in Mexico, Central and South America28-01-2016 07:55Jan 28 (Reuters) – Skyepharma Plc :Mundipharma appointed as development and marketing partner for Flutiform in Mexico, Central and South AmericaSource text for Eikon: ... Further company coverage: SKP.L(Bengaluru Newsroom: +91 80 6749 1136)
dave297
28 Jan 2016
Good News ? Fluti to be marketed in Mexico,Central & South America by Mundipharm (rather than Sanofi),although Sanofi will continue manufacturing Fluti in UK.There must be substantial potential in S America for Fluti & Mundi are well placed to exploit it so,sounds like good news to me .Perhaps Sanofi had conflicts of interest in that region or just had not got their act together there.
Ambiorix1
11 Jan 2016
Re: Pre Close Update An excellent update indeed, for which I am particularly glad since I have been pushing this share on this board quiet heavily over the last few weeks. Those who followed my thinking are sitting on a nice gain today, even those who bought early this morning after I noticed the change in the Zackx rating on Saturday. It must be said that before this change Pacira had a rating of 3 which is nothing else as “just leave it for the moment”. And indeed even if nothing new is added, 2016 will be a good year for SKP. All the rest is a bonus. But if Pacira manages to expand the use of Exparel then this bonus could be huge. Why ? Who is associated with SKP for the promotion of Flutiform ? It’s Mundipharma. And who are they? One of the leaders in the US specialised in pain management. Have a closer look at their website. It states this (quote) ” At Mundipharma we are thinking differently about pain.We know we can't always cure people's pain but we can re-address the pain-life balance – shifting people's experiences away from pain and back towards the full enjoyment of life.The Mundipharma network of independent associated companies has a proven track record of bringing pain innovations to market, successfully launching Palladon®, MST ®, Targin®,BuTrans® and OxyContin®.But we believe that for people living in pain, and for those treating and caring for them, the job is far from done. Collaborating with our partners and the people who make treatment decisions, we are working to identify remaining unmet needs.Got the picture ? No ? To bad.Ambiorix.
dave297
11 Jan 2016
Pre Close Update Continues the positive theme , the inference being that 2016 could be a very good year for us as our portfolio of products developes further & our cash flow continues to be positive which should be assisted further by the $250mill milestone from Pacira( of $8mill) which will surely be received this year .That ,of course, is without any new products/developments which may emerge this year ( including my longstanding wish/hope that Fluti will be represented in the US by someone)
raptor66
10 Jan 2016
Re: Edison's notes on SKP [link]
raptor66
10 Jan 2016
Edison's notes on SKP [link]
